{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-076715","form_type":"8-K","ticker":"SXTP","cik":"0001946563","company_name":"60 DEGREES PHARMACEUTICALS, INC.","filed_at":"2026-07-09T20:05:54+00:00","discovered_at":"2026-07-09T20:07:14.622089+00:00","generated_at":"2026-07-09T20:07:28.330268+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"60 Degrees files SAP for tafenoquine babesiosis trial; interim analysis criteria set","bullets":["23 of 33 planned patients enrolled in randomized, placebo-controlled trial of tafenoquine for severe babesiosis (NCT0627370).","Interim analysis at earlier of 10/30/26 or after 24 patients randomized and followed ≥50 days.","Conditional power ≥80% for TTSCR with p≤0.02137 triggers early reporting; 50-80% triggers sample size reassessment (capped at 66 total).","Company intends to apply for a National Priority Review Voucher if results support sNDA submission before Q1 2028.","Sponsor and investigators remain blinded to interim analysis results if study continues."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-076715","json":"https://secwatch.observer/filing/0001213900-26-076715.json","markdown":"https://secwatch.observer/filing/0001213900-26-076715.md","text":"https://secwatch.observer/filing/0001213900-26-076715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026076715/0001213900-26-076715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1946563/000121390026076715/ea0297549-8k_60degrees.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-09T20:07:28.330268+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}